3 treatment settings, 2 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.
Wide resection with pre- or postoperative radiotherapy; neoadjuvant or adjuvant ifosfamide-doxorubicin for large high-risk tumours.
IMRT and IGRT shape the radiation beam to the tumour's outline from multiple angles and check the patient's position with a scan before every session, so surrounding organs receive less dose. Fewer, larger doses are now standard in breast and prostate cancer, but a low-dose bath still spreads across normal tissue.
Ifosfamide is an alkylating chemotherapy partnered with doxorubicin in sarcoma and with etoposide in Ewing sarcoma, given with a bladder-protecting drug.
The red chemotherapy drug from a soil bacterium that is still the backbone of treatment for sarcoma, lymphoma and breast cancer, limited by cumulative heart damage.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Febrile neutropenia (with doxorubicin) · EORTC 62012, intensified doxorubicin plus ifosfamide arm (103 of 224); 13% with doxorubicin alone | - | 46% |
| Central nervous system toxicity, including encephalopathy · Ifosfamide monotherapy trials pooled in the label (154 of 1001) | 15.4% | - |
| Visible blood in the urine (macroscopic haematuria) · With mesna, ifosfamide monotherapy trials pooled in the label (5 of 97); 11.1% without mesna | 5.2% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia · Doxorubicin 75 mg/m2 with placebo, ANNOUNCE control arm (49.0%) | - | 49% |
| Alopecia · Doxorubicin with cyclophosphamide (AC), adjuvant breast cancer, N=1492; the label gives no sarcoma figure | 92% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.
Ifosfamide-based chemotherapy, doxorubicin; pazopanib or trabectedin later.
Ifosfamide is an alkylating chemotherapy partnered with doxorubicin in sarcoma and with etoposide in Ewing sarcoma, given with a bladder-protecting drug.
The red chemotherapy drug from a soil bacterium that is still the backbone of treatment for sarcoma, lymphoma and breast cancer, limited by cumulative heart damage.
Pazopanib is the only multi-kinase inhibitor approved for soft-tissue sarcoma (excluding fat-derived tumours), used after chemotherapy fails.
A chemotherapy derived from a sea squirt, used with liposomal doxorubicin in relapsed ovarian cancer in Europe and for sarcomas.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Febrile neutropenia (with doxorubicin) · EORTC 62012, intensified doxorubicin plus ifosfamide arm (103 of 224); 13% with doxorubicin alone | - | 46% |
| Central nervous system toxicity, including encephalopathy · Ifosfamide monotherapy trials pooled in the label (154 of 1001) | 15.4% | - |
| Visible blood in the urine (macroscopic haematuria) · With mesna, ifosfamide monotherapy trials pooled in the label (5 of 97); 11.1% without mesna | 5.2% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia · Doxorubicin 75 mg/m2 with placebo, ANNOUNCE control arm (49.0%) | - | 49% |
| Alopecia · Doxorubicin with cyclophosphamide (AC), adjuvant breast cancer, N=1492; the label gives no sarcoma figure | 92% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Fatigue · PALETTE (VEG110727) pazopanib arm, N=240 | 65% | 14% |
| ALT elevation · PALETTE (VEG110727) pazopanib arm, laboratory data | 46% | 10% |
| Hypertension · PALETTE (VEG110727) pazopanib arm, N=240 | 42% | 7% |
| Pneumothorax · PALETTE (VEG110727), 8 of 240 patients | 3.3% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia · ET743-SAR-3007, trabectedin alone in liposarcoma or leiomyosarcoma, laboratory values, US label; the OVA-301 combination abstract gives no rate | 66% | 43% |
| ALT increase · ET743-SAR-3007, trabectedin alone, laboratory values, US label; OVA-301 reported grade 3-4 transaminase rises as more common with the combination but transient | 90% | 31% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.
Afamitresgene autoleucel after chemotherapy; NY-ESO-1 TCR therapy in trials.
Afamitresgene autoleucel was the first engineered T-cell receptor therapy approved for a solid tumour, synovial sarcoma.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
No side-effect rates or interaction flags are recorded for these options yet. The side-effect lookup and interaction checker cover the products that have them.
Add these to your appointment list, or take the full question set for this cancer.